The stock of Ocugen Inc (OCGN) has gone down by -10.06% for the week, with a 13.43% rise in the past month and a 38.36% rise in the past quarter. The volatility ratio for the week is 4.21%, and the volatility levels for the past 30 days are 4.72% for OCGN. The simple moving average for the last 20 days is 6.89% for OCGN stock, with a simple moving average of -1.98% for the last 200 days.
Is It Worth Investing in Ocugen Inc (NASDAQ: OCGN) Right Now?
The 36-month beta value for OCGN is also noteworthy at 4.21. There are mixed opinions on the stock, with 2 analysts rating it as a “buy,” 2 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for OCGN is 286.77M, and at present, short sellers hold a 24.27% of that float. The average trading volume of OCGN on June 03, 2025 was 4.18M shares.
OCGN) stock’s latest price update
Ocugen Inc (NASDAQ: OCGN)’s stock price has increased by 0.13 compared to its previous closing price of 0.84. However, the company has seen a -10.06% decrease in its stock price over the last five trading sessions. globenewswire.com reported 2025-05-27 that MALVERN, Pa., May 27, 2025 (GLOBE NEWSWIRE) — Ocugen, Inc. (Ocugen or the Company) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced that the United States Food and Drug Administration (U.S. FDA) has granted Rare Pediatric Disease Designation (RPDD) for OCU410ST for the treatment of ABCA4-associated retinopathies including Stargardt disease, retinitis pigmentosa 19, and cone-rod dystrophy 3. Previously, OCU410ST received Orphan Drug designations for the treatment of ABCA4-associated retinopathies from the FDA and European Medicines Agency.
Analysts’ Opinion of OCGN
Many brokerage firms have already submitted their reports for OCGN stocks, with Maxim Group repeating the rating for OCGN by listing it as a “Buy.” The predicted price for OCGN in the upcoming period, according to Maxim Group is $4 based on the research report published on October 15, 2024 of the previous year 2024.
Chardan Capital Markets, on the other hand, stated in their research note that they expect to see OCGN reach a price target of $3.50. The rating they have provided for OCGN stocks is “Buy” according to the report published on March 01st, 2023.
Mizuho gave a rating of “Buy” to OCGN, setting the target price at $5 in the report published on August 23rd of the previous year.
OCGN Trading at 14.88% from the 50-Day Moving Average
After a stumble in the market that brought OCGN to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -57.70% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at OCGN starting from Fernandes Prabhavathi, who purchase 10,000 shares at the price of $0.91 back on Nov 26 ’24. After this action, Fernandes Prabhavathi now owns 10,000 shares of Ocugen Inc, valued at $9,095 using the latest closing price.
Castillo Kirsten, the Director of Ocugen Inc, purchase 25,000 shares at $0.91 during a trade that took place back on Nov 22 ’24, which means that Castillo Kirsten is holding 75,000 shares at $22,848 based on the most recent closing price.
Stock Fundamentals for OCGN
Current profitability levels for the company are sitting at:
- -12.61 for the present operating margin
- 1.0 for the gross margin
The net margin for Ocugen Inc stands at -12.71. The total capital return value is set at -1.2. Equity return is now at value -248.97, with -98.89 for asset returns.
Based on Ocugen Inc (OCGN), the company’s capital structure generated 0.21 points at debt to capital in total, while cash flow to debt ratio is standing at -12.25. The debt to equity ratio resting at 0.26. The interest coverage ratio of the stock is -62.41.
Currently, EBITDA for the company is -52.79 million with net debt to EBITDA at 0.62. When we switch over and look at the enterprise to sales, we see a ratio of 46.63. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.60.
Conclusion
In summary, Ocugen Inc (OCGN) has had a mixed performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
